Kevin Sayer is the president, chairman, and CEO of Dexcom, a company that develops, manufactures, and distributes continuous glucose monitoring systems.
Sayer joined Dexcom as its president and chief operating officer in 2011, and he became CEO in 2015. In his various roles, he has directed research and development, manufacturing, regulatory, clinical, finance, marketing, and sales functions.
He has played a leading role in developing new technologies in the United States and Europe, including the Dexcom G5 Mobile CGM System and the Dexcom G4 PLATINUM System with Share, among others.
Before joining Dexcom, Sayer was the chief financial officer for medical technology company, Biosensors International. He has also served as an independent healthcare and medical technology industry consultant, as the executive vice president and CFO for Specialty Laboratories, and as the CFO of MiniMed from 1994 until 2001, when it was acquired by Medtronic.
Sayer was recognized on Forbes’ “Innovative Leaders” list in 2019.
He earned both his B.S. and M.S. in accounting and information systems at Brigham Young University.
Within the last three months, Kevin R.. Sayer has sold $2,281,054.00 in shares of DexCom stock. Most recently, Kevin R. Sayer sold 6,221 shares of the business's stock in a transaction on Monday, April 5th. The shares were sold at an average price of $366.67, for a transaction totalling $2,281,054.07.